Bio-Rad Laboratories (BIO) Research Coverage Started at Goldman Sachs Group

Goldman Sachs Group initiated coverage on shares of Bio-Rad Laboratories (NYSE:BIO) in a research report report published on Wednesday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $350.00 price objective on the medical research company’s stock.

A number of other equities research analysts have also recently commented on the stock. Jefferies Financial Group reiterated a buy rating and issued a $420.00 target price on shares of Bio-Rad Laboratories in a research report on Monday, September 24th. Morgan Stanley started coverage on shares of Bio-Rad Laboratories in a research report on Thursday, September 20th. They set an equal weight rating and a $335.00 price objective for the company. Barclays started coverage on shares of Bio-Rad Laboratories in a research report on Wednesday, September 5th. They set an equal weight rating and a $345.00 price objective for the company. Finally, Zacks Investment Research cut shares of Bio-Rad Laboratories from a buy rating to a hold rating in a research report on Monday, August 13th. Four analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock currently has a consensus rating of Buy and an average target price of $342.71.

Shares of NYSE BIO opened at $280.96 on Wednesday. The stock has a market capitalization of $8.49 billion, a PE ratio of 54.49, a price-to-earnings-growth ratio of 2.97 and a beta of 0.96. The company has a quick ratio of 3.17, a current ratio of 4.50 and a debt-to-equity ratio of 0.09. Bio-Rad Laboratories has a 52 week low of $214.44 and a 52 week high of $345.15.

Bio-Rad Laboratories (NYSE:BIO) last issued its earnings results on Tuesday, August 7th. The medical research company reported $1.64 EPS for the quarter, beating the Zacks’ consensus estimate of $1.27 by $0.37. The business had revenue of $575.91 million during the quarter, compared to analysts’ expectations of $551.05 million. Bio-Rad Laboratories had a net margin of 44.77% and a return on equity of 4.23%. As a group, equities research analysts predict that Bio-Rad Laboratories will post 6.38 EPS for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the stock. Boussard & Gavaudan Investment Management LLP acquired a new stake in Bio-Rad Laboratories during the third quarter worth about $202,000. Raymond James Trust N.A. purchased a new position in Bio-Rad Laboratories during the second quarter worth about $212,000. World Asset Management Inc purchased a new position in Bio-Rad Laboratories during the second quarter worth about $213,000. We Are One Seven LLC purchased a new position in Bio-Rad Laboratories during the third quarter worth about $254,000. Finally, Atria Investments LLC purchased a new position in Bio-Rad Laboratories during the third quarter worth about $337,000. Hedge funds and other institutional investors own 63.21% of the company’s stock.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.

Recommended Story: What are earnings reports?

Analyst Recommendations for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply